Healthcare / BiotechnologyASX
$0.11
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-4.3M · quality 54.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-22.9%
↓Gross Margin
100.0%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-3254.4%
FCF / Net income
1.20x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $152240.0 · net income $-4.1M · FCF $-5.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $152240.00 | $152240.00 | $3076.00 | — | — |
| Net Income | $-4.1M | $-4.1M | $-4.2M | $-6.8M | — |
| EBITDA | $-6.5M | $-6.5M | $-5.7M | $-6.8M | — |
| EPS | -0.07 | -0.07 | -0.07 | -0.14 | — |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Operating Margin | -4280.3% | -4280.3% | -186616.8% | — | — |
| Net Margin | -2718.1% | -2718.1% | -135709.2% | — | — |
| Balance Sheet | |||||
| Current Ratio | 20.46 | 20.46 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-5.0M | $-5.0M | $-4.3M | $-4.0M | — |
| Returns | |||||
| ROE | -22.9% | -22.9% | -19.1% | -27.0% | — |
| Valuation | |||||
| P/B | 0.37 | 0.37 | 0.82 | 0.46 | — |
| Growth & Yield | |||||
| Revenue Growth | 4849.3% | 4849.3% | — | — | — |
| EPS Growth | 0.9% | 0.9% | 49.8% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-40.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.07 → -0.07
Residual
-40.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.